SangStat Medical Surges on Merger News

CV Therapeutics skids; Church & Dwight raises guidance; plus more of today's stocks to watch

Genzyme Corp. (GENZ ) agreed to acquire SangStat Medical Corp. (SANG ) in an all cash transaction valued at $22.50 per SANG share, or about $600 million. The transaction is expected to cause Genzyme's GAAP EPS to be lower due to amortization through 2004. SangStat shares jumped nearly 44% to $22.21 on the merger news.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.